🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are escalating globally, with estimates suggesting in excess of 82 million instances per year. Particularly high rates are observed in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the context of rising global incidence, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The global health body has classified it as a "critical concern". Ongoing monitoring showed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Approval

One new antibiotic, marketed under the name a brand name, was approved by the American regulatory agency in mid-December for use against gonorrhoea. This STI can lead to significant complications, including infertility. Experts believe that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in concurrent days. This medication, which is employed against UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a major breakthrough in the treatment of superbug gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Data and Global Access

As per data detailed in a major medical journal, zoliflodacin eradicated more than 90% of cases of the STI. This puts it on an comparable level with the current standard treatment, which involves a dual-drug approach. The research included over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the rights to make available and distribute the drug in a wide range of developing nations.

Clinicians treating patients have shared optimism. Having a one-pill regimen like this is described as a "revolutionary step" for managing the epidemic. This is considered essential to reduce the burden of the disease for individuals and to halt the transmission of untreatable gonorrhoea globally.